Clinical Trial Update: Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

Phase 3 fixed-dose study investigating PD 0332334 with paroxetine for generalized anxiety disorder was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• PD 0332334
• Paroxetine (Paroxetine hydrochloride)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Anxiety Disorders | Phase 3 | Status: TERMINATED